Roivant Sciences (NASDAQ:ROIV) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of Roivant Sciences (NASDAQ:ROIV) in a research note released on Monday morning, Benzinga reports. The firm currently has a $18.00 target price on the stock.

A number of other analysts also recently issued reports on the stock. Piper Sandler began coverage on shares of Roivant Sciences in a report on Friday, January 5th. They set an overweight rating and a $20.00 price target on the stock. Wolfe Research began coverage on shares of Roivant Sciences in a research note on Thursday, February 15th. They set an outperform rating and a $17.00 target price for the company. The Goldman Sachs Group raised their price target on Roivant Sciences from $16.00 to $18.00 and gave the stock a buy rating in a research note on Wednesday, April 3rd. Deutsche Bank Aktiengesellschaft upped their price objective on Roivant Sciences from $14.00 to $15.00 and gave the company a buy rating in a research report on Wednesday, April 3rd. Finally, Truist Financial restated a buy rating and set a $23.00 price target on shares of Roivant Sciences in a research note on Monday, March 25th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus target price of $16.90.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $10.88 on Monday. The firm has a market cap of $8.77 billion, a P/E ratio of 2.09 and a beta of 1.34. Roivant Sciences has a twelve month low of $8.06 and a twelve month high of $13.24. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average of $10.93 and a 200 day moving average of $10.36.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Tuesday, February 13th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.07. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. The firm had revenue of $37.14 million during the quarter, compared to analysts’ expectations of $30.72 million. As a group, research analysts expect that Roivant Sciences will post -1.36 EPS for the current fiscal year.

Insider Transactions at Roivant Sciences

In other news, COO Eric Venker sold 96,950 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $10.92, for a total value of $1,058,694.00. Following the completion of the transaction, the chief operating officer now owns 532,207 shares of the company’s stock, valued at $5,811,700.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.60% of the company’s stock.

Institutional Trading of Roivant Sciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. FNY Investment Advisers LLC purchased a new position in shares of Roivant Sciences during the fourth quarter valued at about $33,000. Headlands Technologies LLC bought a new stake in Roivant Sciences in the 4th quarter worth approximately $36,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Roivant Sciences during the 3rd quarter worth approximately $44,000. Covestor Ltd boosted its position in shares of Roivant Sciences by 165,040.0% during the 3rd quarter. Covestor Ltd now owns 8,257 shares of the company’s stock valued at $96,000 after acquiring an additional 8,252 shares during the last quarter. Finally, Premier Path Wealth Partners LLC bought a new position in shares of Roivant Sciences during the 1st quarter valued at approximately $126,000. 64.76% of the stock is currently owned by institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.